

This communication should be viewed by:
Dialysis Facilities

Notice Regarding Medicaid and HARP Requirements for Oral-Only Phosphate Binders Effective January 1, 2026

MVP Health Care® (MVP) values your ongoing commitment to our Members and strives to keep you updated on matters impacting your patients.

Beginning January 1, 2026, Phosphate binder prescription drugs for dialysis patients will no longer be covered by NYRx as a pharmacy benefit; these medications must instead be dispensed by the dialysis clinic. The Medicaid payment policy that incorporates phosphate binders into the Fee-For-Service (FFS) dialysis APG rate for Medicaid-only patients will also take effect on January 1, 2026.

As a result, separate reimbursement for these medications will be discontinued, and the cost of oral-only phosphate binders will be included in the bundled payment rate for renal dialysis services. Patients will be directed to obtain these medications from their dialysis center.

Key points

- **Coverage:** All oral only phosphate binder medications for dialysis patients with ESRD, such as sevelamer carbonate, lanthanum carbonate, sucroferric oxyhydroxide, and ferric citrate, are now considered part of the bundled payment and will be reimbursed as such
- **Dispensing responsibility:** As a dialysis facility, you are now responsible for dispensing these oral phosphate binders directly to your ESRD patients
- **Billing implications:** Do not submit separate claims for oral phosphate binders; they will be included in the standard ESRD bundled payment

Please review your medication procedures for Medicaid compliance.

To view all communications, visit mvphealthcare.com/FastFax.

